


J.P. Morgan

42nd Healthcare Conference

Prahlad Singh
Chief Executive Officer

revvity

January 9, 2024



Safe Harbor

This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

Revvity is a company which powers **new possibilities** for the future of human health

revvity

Revolutionizing human health at an accelerated [rev] speed

Embracing the impossible to improve lives [vita]




Our company profile: global scale with differentiated positioning



W

Expanding the boundaries of human potential through science



Life Sciences at-a-glance

~\$1.3B
2023E Revenue


\$20B+
Total Addressable Market

Pioneering innovation to propel our life sciences customers' R&D efforts

\$0.7B
Reagents, Assays,
& Services

- ✓ Reagents (antibodies, oligos) for biomarker analysis
- ✓ Flow-based assays
- ✓ Cell and gene therapy
- ✓ Single-cell applications

Select brands and products



Viral Vectors & Genetic Material

\$0.4B
Instruments

- ✓ Pre-clinical imaging
- ✓ Cellular analysis
- ✓ Detection instrumentation



In Vivo Imaging



High-Content Screening



Automated Cell Counter

\$0.2B
Software

- ✓ Robust solutions, through our Revvity Signals platform, for research and clinical informatics

revvity
signals



Diagnostics at-a-glance

~\$1.4B
2023E Revenue

\$35B+
Total Addressable Market

Leading franchises dedicated to advancing human health

\$0.7B
ImmunoDx


- ✓ Autoimmune
- ✓ Allergy
- ✓ Infectious disease (e.g., TB)

Select brands and products

EUROIMMUN



Auto-immune Assays



Infectious Disease Assays

\$0.5B
Reproductive Health

- ✓ Newborn screening
- ✓ Maternal and fetal health
- ✓ Cord-blood banking
- ✓ Global laboratory footprint



Newborn Screening System




Maternal & Fetal Health Assays



Prenatal Screening Platform

\$0.2B
Applied Genomics

- ✓ Robust 'omics sample prep portfolio
- ✓ Liquid handling
- ✓ Nucleic acid extraction



Nucleic Acid Extraction




Automated NGS Library Prep



NGS Assays


Bringing it all together: powering innovation from Research to Reality






Revvity's Differentiation

Differentiating through our...



Our approach: serving our customers as a strategic partner

Strategic partner for...



Pre-clinical innovation



GMP manufacturing



Global genomic labs



Cutting-edge clinical diagnostics

Partnership Spotlight: PIN-POINT™ BASE EDITING TECHNOLOGY

Multiple
Customer
Access Points

✓ Licensing

✓ Products

✓ Services

May
2023

Clinical

Executed first clinical
licensing agreement with
AstraZeneca for oncology
and immune-related
diseases

Sep
2023

Pre-clinical

Launched reagents to
enable technology
evaluations and
improve functional
insights

Our products: specialized offerings that foster scientific innovation and positively impact human health


Product Spotlights

Enhanced Imaging Portfolio



Quantum GX3
microCT imaging
solution

Proteogenomics & Multiomics Reagents



TotalSeq™

Scientific Data Management & Workflow Platform

revvity
signals
Research
Platform



Automated Indirect Immunofluorescence Testing



UNIQUO
160



Autoimmune
Testing Menu


Automated Newborn Screening Workflow



Eonis™ Q System



*Cutting-edge, high-value products which provide **differentiated** capabilities for customers*

Our positioning: unique portfolio will continue to foster growth and drive attractive profitability profile



Strategic scientific partnerships with Pharma/Biotech across the Revvity portfolio to **drive additional upside** vs. underlying market growth

Our positioning: unique revenue mix in China drives differentiated performance



Current 2023E Guidance assumes +MSD organic growth in China



Looking Ahead


Key focus areas in 2024

Despite uncertain demand environments...



...carrying momentum into Revvity's 2nd year

INNOVATION



Driving **CROSS-COMPANY INNOVATION** & building on core growth accelerators

EFFICIENCY



Capturing **COST EFFICIENCIES** and commercial and operational **SYNERGIES** through sound execution

INVESTMENT




Strategically **DEPLOYING CAPITAL** organically and inorganically

Differentiated long-term outlook through economic cycles

Our outlook for 2025 and beyond:





Revvity.com